These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 19308670)

  • 41. Intrathecal enzyme replacement for cognitive decline in mucopolysaccharidosis type I, a randomized, open-label, controlled pilot study.
    Chen AH; Harmatz P; Nestrasil I; Eisengart JB; King KE; Rudser K; Kaizer AM; Svatkova A; Wakumoto A; Le SQ; Madden J; Young S; Zhang H; Polgreen LE; Dickson PI
    Mol Genet Metab; 2020 Feb; 129(2):80-90. PubMed ID: 31839529
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Enzyme replacement therapy in mucopolysaccharidosis type I.
    Miebach E
    Acta Paediatr Suppl; 2005 Mar; 94(447):58-60; discussion 57. PubMed ID: 15895714
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy of a Combination Therapy with Laronidase and Genistein in Treating Mucopolysaccharidosis Type I in a Mouse Model.
    Malinowska M; Nowicka W; Kloska A; Węgrzyn G; Jakóbkiewicz-Banecka J
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38397051
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Enzyme replacement therapy in an attenuated case of mucopolysaccharidosis type I (Scheie syndrome): a 6.5-year detailed follow-up.
    Jurecka A; Marucha J; Jurkiewicz E; Różdżyńska-Świątkowska A; Tylki-Szymańska A
    Pediatr Neurol; 2012 Dec; 47(6):461-5. PubMed ID: 23127271
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Intrathecal enzyme replacement therapy in a patient with mucopolysaccharidosis type I and symptomatic spinal cord compression.
    Munoz-Rojas MV; Vieira T; Costa R; Fagondes S; John A; Jardim LB; Vedolin LM; Raymundo M; Dickson PI; Kakkis E; Giugliani R
    Am J Med Genet A; 2008 Oct; 146A(19):2538-44. PubMed ID: 18792977
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy of recombinant human alpha-L-iduronidase (laronidase) on restricted range of motion of upper extremities in mucopolysaccharidosis type I patients.
    Tylki-Szymanska A; Marucha J; Jurecka A; Syczewska M; Czartoryska B
    J Inherit Metab Dis; 2010 Apr; 33(2):151-7. PubMed ID: 20217237
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Laronidase-loaded liposomes reach the brain and other hard-to-treat organs after noninvasive nasal administration.
    Schuh RS; Franceschi EP; Brum BB; Fachel FNS; Poletto É; Vera LNP; Santos HS; Medeiros-Neves B; Monteagudo de Barros V; Helena da Rosa Paz A; Baldo G; Matte U; Giugliani R; Ferreira Teixeira H
    Int J Pharm; 2024 Jul; 660():124355. PubMed ID: 38897489
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Growth in individuals with attenuated mucopolysaccharidosis type I during untreated and treated periods: Data from the MPS I registry.
    Polgreen LE; Bay L; Clarke LA; Guffon N; Jones SA; Muenzer J; Flores AL; Wilson K; Viskochil D
    Am J Med Genet A; 2022 Oct; 188(10):2941-2951. PubMed ID: 35869927
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-term and high-dose trials of enzyme replacement therapy in the canine model of mucopolysaccharidosis I.
    Kakkis ED; McEntee MF; Schmidtchen A; Neufeld EF; Ward DA; Gompf RE; Kania S; Bedolla C; Chien SL; Shull RM
    Biochem Mol Med; 1996 Aug; 58(2):156-67. PubMed ID: 8812735
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Early versus late treatment of spinal cord compression with long-term intrathecal enzyme replacement therapy in canine mucopolysaccharidosis type I.
    Dickson PI; Hanson S; McEntee MF; Vite CH; Vogler CA; Mlikotic A; Chen AH; Ponder KP; Haskins ME; Tippin BL; Le SQ; Passage MB; Guerra C; Dierenfeld A; Jens J; Snella E; Kan SH; Ellinwood NM
    Mol Genet Metab; 2010; 101(2-3):115-22. PubMed ID: 20655780
    [TBL] [Abstract][Full Text] [Related]  

  • 51. 18-year follow-up of enzyme-replacement therapy in two siblings with attenuated mucopolysaccharidosis I.
    Pjetraj D; Santoro L; Sgattoni C; Padella L; Zampini L; Monachesi C; Gabrielli O; Catassi C
    Am J Med Genet A; 2023 Feb; 191(2):564-569. PubMed ID: 36333985
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sudden vision loss in a mucopolysaccharidosis I patient receiving enzyme replacement therapy.
    Yosunkaya E; Karaca E; Yilmaz SB; Gezdirici A; Guven G; Seven M; Yuksel A
    Genet Couns; 2011; 22(4):371-6. PubMed ID: 22303797
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of enzyme replacement therapy started late in a murine model of mucopolysaccharidosis type I.
    Pasqualim G; Baldo G; de Carvalho TG; Tavares AM; Giugliani R; Matte U
    PLoS One; 2015; 10(2):e0117271. PubMed ID: 25646802
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Enzyme replacement therapy started at birth improves outcome in difficult-to-treat organs in mucopolysaccharidosis I mice.
    Baldo G; Mayer FQ; Martinelli BZ; de Carvalho TG; Meyer FS; de Oliveira PG; Meurer L; Tavares A; Matte U; Giugliani R
    Mol Genet Metab; 2013 May; 109(1):33-40. PubMed ID: 23562162
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Early treatment with laronidase improves clinical outcomes in patients with attenuated MPS I: a retrospective case series analysis of nine sibships.
    Al-Sannaa NA; Bay L; Barbouth DS; Benhayoun Y; Goizet C; Guelbert N; Jones SA; Kyosen SO; Martins AM; Phornphutkul C; Reig C; Pleat R; Fallet S; Ivanovska Holder I
    Orphanet J Rare Dis; 2015 Oct; 10():131. PubMed ID: 26446585
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Hurler syndrome. Early diagnosis and successful enzyme replacement therapy: a new therapeutic approach. Case report].
    Dupont C; El Hachem C; Harchaoui S; Ribault V; Amiour M; Guillot M; Maire I; Froissart R; Guffon-Fouilhoux N
    Arch Pediatr; 2008 Jan; 15(1):45-9. PubMed ID: 18162380
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Liver-directed gene therapy corrects cardiovascular lesions in feline mucopolysaccharidosis type I.
    Hinderer C; Bell P; Gurda BL; Wang Q; Louboutin JP; Zhu Y; Bagel J; O'Donnell P; Sikora T; Ruane T; Wang P; Haskins ME; Wilson JM
    Proc Natl Acad Sci U S A; 2014 Oct; 111(41):14894-9. PubMed ID: 25267637
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Regression of ventriculomegaly following medical management of a patient with Hurler syndrome.
    Liang J; Singhal A
    J Neurosurg Pediatr; 2016 May; 17(5):537-9. PubMed ID: 26745646
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Biodistribution and pharmacodynamics of recombinant human alpha-L-iduronidase (rhIDU) in mucopolysaccharidosis type I-affected cats following multiple intrathecal administrations.
    Vite CH; Wang P; Patel RT; Walton RM; Walkley SU; Sellers RS; Ellinwood NM; Cheng AS; White JT; O'Neill CA; Haskins M
    Mol Genet Metab; 2011 Jul; 103(3):268-74. PubMed ID: 21482164
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Limited data to evaluate real-world effectiveness of enzyme replacement therapy for mucopolysaccharidosis type I.
    Kuiper GA; Nijmeijer SCM; Roelofs MJM; van der Lee JH; Hollak CEM; Bosch AM
    J Inherit Metab Dis; 2019 Sep; 42(5):762-775. PubMed ID: 31020996
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.